Although early studies described the constitutive lung tissue expression of PARC in humans [8–9], the role of PARC in the physiopathology of COPD and its relationship with the systemic vascular involvement described in this chronic condition are currently unknown [10].A small number of studies suggest that PARC could be a serum biomarker of cardiovascular mortality in large populations of COPD patients [11–12]. Here, CCL18 is linked to chronic obstructive pulmonary disease.